Syndax Pharmaceuticals Inc. presented updates highlighting its progress as a commercial-stage oncology company with three FDA approvals and two launched medicines: Revuforj and Niktimvo. The company reported preliminary full-year 2025 net revenue of approximately $125 million, driven by strong patient demand and the performance of Revuforj. Fourth quarter 2025 net revenue was preliminarily estimated at $44 million, with around 1,150 total prescriptions, reflecting quarter-over-quarter growth. Syndax ended 2025 with a preliminary cash position of $394 million. The presentation also emphasized the continued expansion opportunities for its approved medicines, particularly with Revuforj, which has achieved first-mover status in several acute leukemia subtypes and is seeing increased adoption in relapsed/refractory NPM1m AML. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.